These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

453 related items for PubMed ID: 29480224

  • 1. Monoaminergic Markers Across the Cognitive Spectrum of Lewy Body Disease.
    van der Zee S, Vermeiren Y, Fransen E, Van Dam D, Aerts T, Gerritsen MJ, Spikman JM, van Laar T, De Deyn PP.
    J Parkinsons Dis; 2018; 8(1):71-84. PubMed ID: 29480224
    [Abstract] [Full Text] [Related]

  • 2. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
    Gmitterová K, Gawinecka J, Llorens F, Varges D, Valkovič P, Zerr I.
    Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
    [Abstract] [Full Text] [Related]

  • 3. Sampling issues of cerebrospinal fluid and plasma monoamines: Investigation of the circadian rhythm and rostrocaudal concentration gradient.
    Janssens J, Atmosoerodjo SD, Vermeiren Y, Absalom AR, den Daas I, De Deyn PP.
    Neurochem Int; 2019 Sep; 128():154-162. PubMed ID: 31034914
    [Abstract] [Full Text] [Related]

  • 4. Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders.
    Gmitterova K, Varges D, Schmitz M, Zafar S, Maass F, Lingor P, Zerr I.
    J Alzheimers Dis; 2020 Sep; 73(4):1355-1361. PubMed ID: 31929170
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid and serum MHPG improve Alzheimer's disease versus dementia with Lewy bodies differential diagnosis.
    Janssens J, Vermeiren Y, Fransen E, Aerts T, Van Dam D, Engelborghs S, De Deyn PP.
    Alzheimers Dement (Amst); 2018 Sep; 10():172-181. PubMed ID: 29552632
    [Abstract] [Full Text] [Related]

  • 6. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 7. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, Teunissen CE, Mollenhauer B, Fladby T, Kramberger MG, Bonanni L, Lemstra AW, European DLB consortium.
    J Alzheimers Dis; 2016 Aug 18; 54(1):287-95. PubMed ID: 27567832
    [Abstract] [Full Text] [Related]

  • 8. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
    Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, Vekrelis K, Kapaki E.
    J Neurol; 2018 Oct 18; 265(10):2295-2301. PubMed ID: 30083953
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid levels of alpha-synuclein, amyloid β, tau, phosphorylated tau, and neuron-specific enolase in patients with Parkinson's disease, dementia with Lewy bodies or other neurological disorders: Their relationships with cognition and nuclear medicine imaging findings.
    Katayama T, Sawada J, Kikuchi-Takeguchi S, Kano K, Takahashi K, Saito T, Okizaki A, Hasebe N.
    Neurosci Lett; 2020 Jan 10; 715():134564. PubMed ID: 31733322
    [Abstract] [Full Text] [Related]

  • 10. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A, Stefanis L, Emmanouilidou E, Vekrelis K, Kapaki E.
    J Neural Transm (Vienna); 2020 Mar 10; 127(3):311-322. PubMed ID: 31912280
    [Abstract] [Full Text] [Related]

  • 11. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S, Takao M, Hatsuta H, Nishina Y, Komiya T, Sengoku R, Nakano Y, Uchino A, Sumikura H, Saito Y, Kanemaru K, Murayama S.
    PLoS One; 2017 Mar 10; 12(2):e0171524. PubMed ID: 28166276
    [Abstract] [Full Text] [Related]

  • 12. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ, Logue M, Growdon JH.
    Arch Neurol; 1985 May 10; 42(5):489-92. PubMed ID: 2581531
    [Abstract] [Full Text] [Related]

  • 13. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
    Parnetti L, Tiraboschi P, Lanari A, Peducci M, Padiglioni C, D'Amore C, Pierguidi L, Tambasco N, Rossi A, Calabresi P.
    Biol Psychiatry; 2008 Nov 15; 64(10):850-5. PubMed ID: 18395699
    [Abstract] [Full Text] [Related]

  • 14. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
    Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.
    Neurodegener Dis; 2007 Nov 15; 4(5):366-75. PubMed ID: 17622779
    [Abstract] [Full Text] [Related]

  • 15. No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.
    Hjärpe J, Söderman E, Andreou D, Sedvall GC, Agartz I, Jönsson EG.
    Psychiatry Res; 2018 May 15; 263():30-34. PubMed ID: 29482043
    [Abstract] [Full Text] [Related]

  • 16. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
    Jellinger KA, Korczyn AD.
    BMC Med; 2018 Mar 06; 16(1):34. PubMed ID: 29510692
    [Abstract] [Full Text] [Related]

  • 17. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP, Hényková E, Kaiserová M, Menšíková K, Vaštík M, Mareš J, Hluštík P, Zapletalová J, Strnad M, Stejskal D, Kaňovský P.
    J Neurol Sci; 2014 Aug 15; 343(1-2):120-4. PubMed ID: 24928081
    [Abstract] [Full Text] [Related]

  • 18. Parkinson's and Lewy body dementia CSF biomarkers.
    Parnetti L, Paciotti S, Farotti L, Bellomo G, Sepe FN, Eusebi P.
    Clin Chim Acta; 2019 Aug 15; 495():318-325. PubMed ID: 31051162
    [Abstract] [Full Text] [Related]

  • 19. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.
    Stefani A, Brusa L, Olivola E, Pierantozzi M, Martorana A.
    J Neural Transm (Vienna); 2012 Jul 15; 119(7):861-75. PubMed ID: 22622365
    [Abstract] [Full Text] [Related]

  • 20. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.
    Lancet Neurol; 2011 Mar 15; 10(3):230-40. PubMed ID: 21317042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.